Biogen’s tau drug diranersen gets a CTAD spotlight

Coverage, in order

1. 7d ago
   
   Longevity.Technology UK indie study

   Biogen’s tau drug diranersen gets a CTAD spotlight

   A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the brain. Alzheimer’s research has spent decades on amyloid, the sticky protein that clumps between brain cells. Tau is the other suspect, and it gets less of the glory. Biogen…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.